The End-Point Mess
Mariell Jessup, MD I n 1986, the landmark vasodilator trial, the VasodilatorHeart Failure Trial (V-HeFT-1), ushered in a modern therapeutic regimen that provided hope, for the first time, to millions of patients suffering from and dying of heart failure. 1 Entry criteria for the trial were simple and confined to men with "impaired cardiac function and reduced exercise tolerance." The primary end point was all-cause mortality. Most clinicians did not quibble about the borderline statistical significance of the overall study, recognizing that a new era of heart failure therapy and clinical trials had begun. The Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) 2 and Studies of Left Ventricular Dysfunction (SOLVD) 3 were published subsequently, in 1987 and 1991, respectively, further refining patient selection while molding a new generation of cardiologists, many of whom became heart failure specialists.
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Since those heady times, the evolution of therapy for heart failure has become increasingly complex. The managing clinician must integrate a number of factors about the individual heart failure patient before adding treatments to the pharmacological foundation of renin-angiotensin and ␤-adrenergic inhibition. Crucial historical or phenotypic variables may include left ventricular ejection fraction (LVEF), functional classification and/or exercise tolerance, history and timing of previous arrhythmias or myocardial infarction, QRS duration and current rhythm, duration of heart failure symptoms, adequacy of or intolerance to optimization of medical therapy, gender, race, cause of the cardiomyopathy, valvular competence, and renal function. Important patient characteristics currently determine eligibility for additional medications, electric devices, surgical procedures, cardiac transplantation, ventricular assist devices, endomyocardial biopsy, cardiac rehabilitation, hospitalization, or hospice. This process of exacting classification of disease has served other disciplines well; imagine outcome trials for the wide range of thrombolytic or antiplatelet agents without the concomitant and careful descriptors of the manifestations of the acute coronary syndrome. 4 Likewise, the oncology community uses an increasingly precise language to further improve their staged battle again malignancy. Witness the narrative received from an oncological consultant about a patient categorized on the cardiac chart as having amyloid with moderate heart failure: "This 59 year-old man with primary (AL) amyloidosis, demonstrated by amyloid deposition on cardiac biopsy (with IHC stains consistent with lambda light chain deposition), elevated serum free lambda light chains, and faint lambda light chains visible on SPEP. It is manifested as class II heart failure, with possible tongue enlargement but no evidence of peripheral nerve, liver, gastrointestinal, or renal deposition. With 10% to 15% monoclonal bone marrow plasma cells, he also had a diagnosis of lambda light chain multiple myeloma, though there is no evidence of myeloma bone disease."
Although the sophistication of the above taxonomy may inspire us, it also compels us to reexamine our heavy reliance on the New York Heart Association (NYHA) functional classification, initially published in 1928 and last revised 16 years ago. 5 Why are we still using this venerable but old and subjective tool that may change with a bolus of furosemide or the whim of a different investigator? Certainly, the NYHA class does correlate with outcome, but so do countless other factors that more objectively measure functional capacity. In an attempt to squeeze some value out of the NYHA class, trialists are further parsing the score into subcategories or with modifiers. For example, 2 recent high-profile trials with otherwise noteworthy and significant results described their entry criteria as follows: "[P]atients of either sex . . . could participate if they had ischemic cardiomyopathy (NYHA class I or II) or nonischemic cardiomyopathy (NYHA class II only), sinus rhythm, an LVEF of 30% or less, and a QRS duration of 130 ms or more, . . . Patients were excluded from enrollment for a variety of reasons, including NYHA class III or IV symptoms," 6 and "Enrolled patients met the following criteria: a LVEF of less than 25%; a peak oxygen consumption of less than 14 mL per kilogram of body weight per minute, or less than 50% of the predicted value; and NYHA class IIIB or IV symptoms for at least 45 of the 60 days before enrollment or dependence on an intra-aortic balloon pump for a period of 7 days or inotropes for a period of at least 14 days before enrollment." 7 The issues that arise about the patients enrolled in these 2 trials may be the subject of great debate and lots of regulatory headaches but will be a major challenge to clinicians who need to make rational choices about expensive therapy for the patient in their office.
As an alternative approach, the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), a mandatory registry for all patients implanted with approved ventricular assist devices, resolved to further describe the clinical profiles of the NYHA class IV patients undergoing surgery, as summarized in Table 1 . 8 Six profile characterizations supplanted the NYHA class IV designation; their description subsequently proved to determine profile-specific outcomes after ventricular assist device implantation. 9 It would not have been possible to discern these differences had all of the patients been registered only as NYHA class IV. Moving forward, it might be possible to further delineate the genetic, biochemical, structural, and systemic correlates of each profile in a precise nomenclature of heart failure that will rival the oncological realm.
Patient entry criteria for clinical trials and recommended therapy are problematic but pale in comparison to the conundrum of study end points in heart failure studies.
Clinical trials designed to demonstrate efficacy of a new treatment have become progressively challenged to pinpoint a precise therapeutic target, one that can be reached by the largest cohort of patients who are reasonably expected to derive benefit. Yusuf and Negassa 10 elegantly summarized their recommendations in 2002, suggesting that "the use of cause-specific events increases sensitivity and decreases biases when used as the primary outcome measure in clinical trials. The choice of the outcome for a trial should balance biological plausibility, robustness of classification, and relative frequency of events." Unfortunately, experts worldwide continue to debate the wisdom of one composite end point over another, 11 and each subsequent trial is ever so subtly different (Table 2) , 6, 7, [12] [13] [14] [15] making comparisons of effectiveness between therapies tricky.
In this issue of Circulation, Fornwalt and coauthors 15 carefully evaluate different primary response criteria from 26 resynchronization therapy trials. The level of agreement among 15 of the primary end points is poor, and the percentage of patients defined as having a positive "response" to chronic resynchronization therapy ranges from 32% to 91%. A full 99% of patients are classified as a responder by at least 1 of the 15 criteria, but 94% are likewise categorized as a nonresponder by at least 1 primary end point. A more disturbing inconsistency uncovered in this study is the variability in which death is considered a nonresponse to chronic resynchronization therapy.
The lack of concordance or unanimity about end points has not been confined to chronic resynchronization therapy trials. The 6-minute corridor test, routinely used to measure functional capacity and to assess response to therapy, served poorly in the latter function. 16 Improvement in peak oxygen capacity (VO 2 max) has proved to be a major hurdle for regulatory approval of new devices and has not been shown conclusively to predict morbidity or mortality after an intervention. A review of lessons learned from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) 17, 18 and Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) 14 trials, both of which explored the management of patients hospitalized with heart failure, suggests that total diuretic dose used does not correlate with observed weight loss but may adversely affect outcomes. Moreover, documented weight loss, which typically corresponds to improvement in dyspnea scores and pedal edema, does not show a relationship with clinical outcomes such as cardiovascular mortality or readmission for heart failure. Indeed, there is currently intense scrutiny about hospital readmissions for heart failure, an end point used in many composite end-point scores, except for the ventricular assist device trials. In these trials, rehospitalization rates have been relegated to a subgroup analysis and calculated only after the patient has been discharged from the index surgical admission. 7, 13 Thus, end points critical for success in one heart failure study have either been shown to be poorly predictive of salutary clinical outcomes in another trial or been consigned to the list of adverse events in a subsequent publication.
Superimposed on this density of decision making is the ever-growing world of "facilitators of quality" that include multiple clinical practice guidelines for heart failure, all of which interpret the same data with subtle shades of difference: the Centers for Medicare and Medicaid Services, Food and Drug Agency, Joint Commission on Accreditation of Healthcare Organizations, National Quality Forum's Core Measures Collection, Pay for Performance, Get With the Guidelines, and individual hospital initiatives to decrease heart failure hospital readmissions, to name just a few. Well-meaning efforts to improve the quality of care delivered to heart failure patients has necessitated an army of coders and data analysts to examine how clinicians practice, thus far resulting in questionable value for our labor. 19, 20 It has become increasingly imperative that any new or expanded use of therapy be accompanied by clear, easily assessed and verifiable eligibility criteria so that busy clinicians can develop systems of care that quickly review and document potential candidates for the new approaches. Ideally, this process should be accomplished by a quick interrogation of the electronic medical record and should not rely on a subjective assessment of functional status. The classification of heart failure patients must move beyond the traditional measures of NYHA and LVEF to incorporate the full spectrum of the syndrome with objective and reproducible measures of disease progression. Finally, the heart failure community must develop a standard composite outcome for trials enrolling hospitalized patients and for those entered as outpatients that can be applied broadly to clinical trials. Only then we will be able to determine the true value of the next big thing.
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